LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Sábháilte in:

Sonraí bibleagrafaíochta
Foilsithe in:	Open Forum Infectious Diseases vol. 5 (Nov 2018), p. S759
Príomhchruthaitheoir:	Kumar, Princy
Rannpháirtithe:	Johnson, Margaret, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Mallolas, Josep, Zhou, Yan, Morais, Cristiana, Kumar, Sushma, Sklar, Peter, Hanna, George J, Hwang, Carey, Greaves, Wayne
Foilsithe / Cruthaithe:	Oxford University Press
Ábhair:	Merck & Co Inc Food & Drug Administration > FDA Merck Sharp & Dohme Stock options Stockholders Infectious diseases Infections Hospitals Advisors Antibiotics High density lipoprotein
Rochtain ar líne:	Citation/Abstract Full Text - PDF
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!